GlaxoSmithKline PLC

GlaxoSmithKline is a global healthcare company. Co.'s segments include: Pharmaceuticals; Vaccines; and Consumer Healthcare. The Pharmaceuticals segment is focused on developing new medicines in respiratory, HIV, oncology and immuno-inflammation, with discovery research exploring these and other areas. The Vaccines segment has a portfolio and pipeline of vaccines to help protect people throughout life. Co. delivers vaccines to people living in over 160 countries. The Consumer Healthcare segment develops and markets consumer-preferred brands in oral health, pain relief, respiratory, nutrition/gastro-intestinal and skin health.
  • TickerGSK
  • ISINGB0009252882
  • ExchangeLondon Stock Exchange
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited Kingdom

Analysts

Damien Conover

Morningstar | GSK Updated Forecasts and Estimates from 05 Nov 2018

GlaxoSmithKline reported third-quarter results largely in line with our expectations and slightly ahead of consensus expectations, but we don't expect any changes to our fair value estimate based on the results. We continue to view the stock as undervalued with the market likely not appreciating Glaxo's accelerating growth following the potential near-term U.S. generic Advair pressure in 2019. New product launches in vaccines are helping mitigate pricing pressures on older respiratory drugs, leading to overall sales growth of 6%, but we expect this growth rate will slow in 2019 as U.S. generi...

Jérôme VINERIER

Analyse court terme - GLAXOSMITHKLINE : La tendance est incertaine.

La tendance est incertaine. Les cours se sont repris, mais la tendance manque de puissance pour le moment. La prochaine résistance est à 1 625,00 p.

Jérôme VINERIER

Short term view - GLAXOSMITHKLINE : The trend is uncertain.

The trend is uncertain. Prices have recovered but the trend lacks power for the time being. The next resistance is at 1,625.00 p.

Eric Le Berrigaud

GLAXOSMITHKLINE - NEUTRAL | 1670p(+9%) Not so easy over the next two years

GLAXOSMITHKLINE - NEUTRAL | 1670p(+9%) Not so easy over the next two years Investments started to weigh on Pharma margins in Q3 More competition for the Respiratory franchise Price pressure in HIV Shingrix will have a bumpy growth

Ahmed Ben Salem ...
  • Antoine Boivin-Champeaux
  • Christophe-Raphaël Ganet
  • Igor Kim
  • Jean Sassus
  • Jean-Baptiste Rouphael
  • Martial Descoutures
  • Pierre Corby
  • Roland Pfaender
  • Steven Gould
  • Valentin Pernet
  • Yan Derocles
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/01/2018

...

GlaxoSmithKline plc: Update to credit analysis

A strong business profile partly offset by somewhat weak credit metrics following the buyout of Novartis's stake in consumer health JV

GlaxoSmithKline plc - June 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GlaxoSmithKline plc - March 2018 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GlaxoSmithKline plc - December 2017 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

GlaxoSmithKline plc: Update following acquisition of Novartis's stake in consumer health JV

Comment on credit implications following GSK's $13 billion acquisition of Novartis's 36.5% in consumer health JV

Damien Conover

Morningstar | GSK Updated Forecasts and Estimates from 05 Nov 2018

GlaxoSmithKline reported third-quarter results largely in line with our expectations and slightly ahead of consensus expectations, but we don't expect any changes to our fair value estimate based on the results. We continue to view the stock as undervalued with the market likely not appreciating Glaxo's accelerating growth following the potential near-term U.S. generic Advair pressure in 2019. New product launches in vaccines are helping mitigate pricing pressures on older respiratory drugs, leading to overall sales growth of 6%, but we expect this growth rate will slow in 2019 as U.S. generi...

Eric Le Berrigaud

GLAXOSMITHKLINE - NEUTRAL | 1670p(+9%) Not so easy over the next two years

GLAXOSMITHKLINE - NEUTRAL | 1670p(+9%) Not so easy over the next two years Investments started to weigh on Pharma margins in Q3 More competition for the Respiratory franchise Price pressure in HIV Shingrix will have a bumpy growth

Martial Descoutures ...
  • Pierre Corby

GlaxoSmithKline : Shingrix and Advair boost the figures… but only temporarily

>Q3 2018 earnings topped expectations … but were of average quality - GSK reported intraday yesterday Q3 2018 results that exceeded expectations at the bottom line. EPS were +7% ahead of expectations due to strong resilience from Advair, a good performance from Shingrix and efforts on margins (improvement in the gross margin and reduction in R&D costs). The group's guidance is adjusted to the upper end of the initial range, i.e. EPS growth between +8 and +10% CER (vs ...

Martial Descoutures ...
  • Pierre Corby

GlaxoSmithKline : Shingrix et Advair boostent les chiffres… mais de façon transitoire

>Une publication T3 supérieure aux attentes … mais de qualité moyenne - GSK publiait hier en séance des résultats du T3 2018 supérieurs aux attentes au niveau de la bottom line. Les BPA sont ressortis +7% au-dessus des attentes du fait d’une forte résistance d’Advair, d’une bonne performance de Shingrix et d’un travail au niveau de la marge (amélioration de la marge brute et diminution des coûts de R&D). La guidance a été ajustée dans le haut de fourchette initiale à ...

Damien Conover

Morningstar | Glaxo Posts 3Q in Line With Our Expectations and Continues to Look Undervalued

GlaxoSmithKline reported third-quarter results largely in line with our expectations and slightly ahead of consensus expectations, but we don't expect any changes to our fair value estimate based on the results. We continue to view the stock as undervalued with the market likely not appreciating Glaxo's accelerating growth following the potential near-term U.S. generic Advair pressure in 2019. New product launches in vaccines are helping mitigate pricing pressures on older respiratory drugs, leading to overall sales growth of 6%, but we expect this growth rate will slow in 2019 as U.S. generi...

1 director sold

A director at GlaxoSmithKline sold 30,000 shares at 1,604p and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board m...

Eric Monnier

Top Picks Q2 Healthcare: From five names down to three

The least we can say about Q1 2018 is that it was another tough quarter for healthcare in general with few exceptions across the sector, despite early activity on the M&A front with Sanofi announcing the acquisitions of Bioverativ and Ablynx in January. This was not enough to prevent the sector from underperforming the general indices by 1.4pp (-6% in absolute terms). We assume this is mainly the reflection of shy 2018 guidance on average from most companies suggesting in the end another transition year with very limited growth, most of which coming from the positive impact of the US tax refor...

Ahmed Ben Salem ...
  • Antoine Boivin-Champeaux
  • Christophe-Raphaël Ganet
  • Igor Kim
  • Jean Sassus
  • Jean-Baptiste Rouphael
  • Martial Descoutures
  • Pierre Corby
  • Roland Pfaender
  • Steven Gould
  • Valentin Pernet
  • Yan Derocles
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 11/01/2018

...

Ahmed Ben Salem ...
  • Antoine Boivin-Champeaux
  • Christophe-Raphaël Ganet
  • Igor Kim
  • Jean Sassus
  • Jean-Baptiste Rouphael
  • Martial Descoutures
  • Pierre Corby
  • Roland Pfaender
  • Steven Gould
  • Valentin Pernet
  • Yan Derocles
  • Yassine Batini

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 01/11/2018

...

Aurelien Sivignon ...
  • Charles Lepetitpas
  • Christophe-Raphaël Ganet
  • Emmanuel Matot
  • Jean-François Granjon
  • Jeremy Garnier
  • Jerôme Bodin
  • Michael Foundoukidis
  • Nicolas David
  • Salma Bouraoui
  • Sven Edelfelt
  • Team Pharma
  • Virginie Rousseau

ODDO BHF Small & MIDCAP MORNING NEWS - 10/26/2018 Date Performance since listing Date Performance since listing

...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Baptiste Lebacq
  • Christophe Chaput
  • Delphine Brault
  • Emira Sagaama
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jerôme Bodin
  • Léopold Authié
  • Matthias Desmarais
  • Michael Foundoukidis
  • Olfa Taamallah
  • Olivier Lebrun
  • Pierre Tegner
  • Rémi Adam
  • Samantha Jeary
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 10/26/2018

...

Ahmed Ben Salem ...
  • Alexandre Iatrides
  • Alfred Glaser
  • Antoine Boivin-Champeaux
  • Baptiste Lebacq
  • Christophe Chaput
  • Delphine Brault
  • Emira Sagaama
  • Fatma Agnès Hamdani
  • Florent Laroche-Joubert
  • François Maury
  • Georges Dieng
  • Jerôme Bodin
  • Léopold Authié
  • Matthias Desmarais
  • Michael Foundoukidis
  • Olfa Taamallah
  • Olivier Lebrun
  • Pierre Tegner
  • Rémi Adam
  • Samantha Jeary
  • Stephane Houri
  • Sven Edelfelt
  • Team Pharma
  • Virginie Rousseau

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 26/10/2018

...

Nurhayati Wan

GlaxoSmithKline Plc

Nurhayati Wan

GlaxoSmithKline Plc

Nurhayati Wan

GlaxoSmithKline Plc

For GLAXOSMITHKLINE PLC., the environment deterioration entails a downgrade to Neutral

GLAXOSMITHKLINE PLC. (GB), a company active in the Pharmaceuticals industry, now shows a lower overall rating. The independent financial analyst theScreener just confirmed the fundamental rating of 2 stars out of 4, as well as the stock market behaviour of the title as moderately risky. However, environmental deterioration penalises the general evaluation, which is downgraded to Neutral. As of the analysis date September 18, 2018, the closing price was GBp 1,486.80 and its expected value was estimated at GBp 1,557.37.

Nurhayati Wan

GlaxoSmithKline Plc

null

GlobalData Department

GlaxoSmithKline Plc (GSK) - Medical Equipment - Deals and Alliances Profile

Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio cover various diseases including...

GlobalData Department

GlaxoSmithKline Plc (GSK) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary GlaxoSmithKline Plc (GSK) is a healthcare company, which focuses on the development, manufacture and commercialization of pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of HIV, respiratory, cancer, immuno-inflammation, anti-virals, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterials, dermatology and rare diseases. The company offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio cover various diseases including...

Dominic Rose ...
  • Naresh Chouhan

New Asthma Drugs Set to Sell $10bn

Five new drugs will drive the Severe Uncontrolled Asthma market from $4bn today to $10bn by 2023. Our bottom-up model shows that biologic drug penetration could almost double by 2023. We see AZN and Sanofi as material winners in the space and show that consensus is likely too low on Tezepelumab, Fasenra & Dupixent. Fasenra is already winning against Nucala (GSK), the P3 Dupixent asthma data has gone underappreciated and consensus models just $200m for Teze in 2023 in AZN numbers.

Dominic Rose ...
  • Naresh Chouhan

Revenue Downgrade Cycle Almost Over

Persistent revenue downgrades have led to investor concern around future analyst forecasts, particularly for new drugs. Our analysis shows that the causes of the sector revenue downgrades have been largely driven by Primary Care launches in the US. More importantly, we show that the downside risk to future new product forecasts has fallen materially. We argue that if forecasts are now more accurate, the recent Pharma sell-off creates a good entry point.

Expert Corporate Governance Service (ECGS)

Etude de l'AG du 04/05/2017

Sir Andrew Witty will be stepping down as CEO with effect from 31 March 2017 and will be succeeded by Emma Walmsley. Dr Patrick Vallance joined the Board in his role as President, R&D on 1 January 2017. Item 2: Approve the Remuneration Report. The remuneration structure is unsatisfactory. Variable remuneration has the potential to be excessive and the actual awards exceeded guidelines. Item 15: Re-appoint the Auditor. PricewaterhouseCoopers LLP (PwC) have been the Group

Jérôme VINERIER

Analyse court terme - GLAXOSMITHKLINE : La tendance est incertaine.

La tendance est incertaine. Les cours se sont repris, mais la tendance manque de puissance pour le moment. La prochaine résistance est à 1 625,00 p.

Jérôme VINERIER

Short term view - GLAXOSMITHKLINE : The trend is uncertain.

The trend is uncertain. Prices have recovered but the trend lacks power for the time being. The next resistance is at 1,625.00 p.

Jérôme VINERIER

Short term view - GLAXOSMITHKLINE : Prices are still making progress

The background trend is clearly bullish. Prices are still making progress but there is less power in the movement. The next resistance is at 1,560.00 p. Breaking below the support at 1,318.00 p would invalidate the trend.

Jérôme VINERIER

Analyse court terme - GLAXOSMITHKLINE : Les cours progressent encore.

La tendance de fond est clairement orientée à la hausse. Les cours progressent encore, mais le mouvement montre moins de puissance. La prochaine résistance est à 1 560,00 p. La rupture du support à 1 318,00 p invaliderait cette tendance.

Jérôme VINERIER

Medium term view - GLAXOSMITHKLINE : The background trend is clearly bullish.

The background trend is clearly bullish. The correction is gaining traction. It is too early to qualify this action as a bearish reversal. The trend would be invalidated below the support at 1,321.00 p.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch